Good the Sandy. you, to everyone on afternoon call. Thank
the began resumption ERT. all final patient biomarkers, investigators of one four that and to our Fabry study ERT. owned were of period progress in a have have study patients patients of execution five taken the from to therapy pleased withdraw and in now Cohort the across each with we successfully stable and and the for pleased in Two fifth treatment the patients replacement wholly STAAR ERT, and the ERT. marked from two not In of another withdrawn report gene off quarter strong withdrawn fitelparvovec an giroctocogene Phase in ERT, second ST-XXX, The in the discussions total X Out adults. been estimation of evaluating additional four I'm programs. I/II are Cohorts have progress required or with clinic that X, therapy of disease enzyme our STAAR program X, for and
for phase XeXX As the from escalation phase, the kilogram quarter the Sandy I/II per Safety dose level. Committee STAAR vector expansion endorsed mentioned, at study Monitoring this Phase the into progressing the genomes
this efficacy total sites are closely imminently and multiple safety and in recruiting, male from female open in and have and patients the including interest patients investigators Italy in Canada, escalation is forward study of including, We owned growing the August. with in the of providing dose candidates. study Inborn both including has annual importantly, to SSIEM, the dose followed phase second been We two first symposium sites end Australia. updated the by XX screening participation now results expect of during A taking to The of STAAR and including community, with therapy the the of patients. the trial I/II Errors at for wholly Metabolism, most place of among XXXX, Society look Fabry from Study half at the Phase
to III with engaging health investigators. and advocacy patient Phase and study continue actively We potential for are authorities, also plan groups
on patients cell known As Sandy we're control manufactured three our PRECIZN-X the June a product wholly manufacturing since the mentioned, dosing. for of owned four have the full Phase sickle of dosed pipeline. XX, events with to be excited candidates BIVVXXX, back study, SARXXXXXX of program process part promising treatment disease, vaso-occlusive I/II as previous continued of we to formerly using In the assumed as free of
now This infusion level who the During crisis. this patient lowest quarter, vaso-occlusive post second achieved of experienced has recovered. fully fetal hemoglobin the patient had the
I/II product final product. study. During in in increase the number to long-term methods using in candidates of the this manufacturing improved internal shown of the Phase been methods These experiments have progenitor quarter, improved manufacturing progressed cells
the sharing look to quarter third We dose study before the the to update forward year incremental data of Phase in patient expect in this the the of and an end year. next I/II
HLA-AX CAR-Tregs III TXXXX Phase study, I/II therapy cell Phase our owned the of kidney manufacturing mismatch addition, a Progress for STEADFAST In continued enabling from activities, groundbreaking actively immune prevention living wholly rejection readiness transplantation continue. in including in mediated the donor. candidate
adverse announcement CAR-Tregs, first patient to the in March historic to be product report our this important an engineered tolerated with We're to believe events. treatment thrilled than we no months have what successfully as believe post Following candidate dose it we been that well with more have the update we first. infusion X is ever a dosed, continues related
the to third dose We patient final first data transplant to cohort. a once complete quarter our in in meaningful to XXXX. quarter package the have This further recently in by dosed the is XXXX. we We Cohort study. later end plan the patient second to STEADFAST disclose from This X for manufacturing hope completed of of be expected received patient kidney and of third and provide we the updates
In Orphan Products. European fewer or Commission Committee Designation, from organ solid granted to European addition, Medicinal a intended the Orphan life for and Designation Product Medicines has be announce in opinion to disease TXXXX for affecting must we treatment for threatening that XX,XXX people. debilitating pleased than this qualify a quarter, chronically are Orphan the positive the To treatment X a Agency transplantation, for following Medicinal
the can must treatment Importantly, rejection, method must of takes medications. to exist, important our no benefit us of come achievement satisfactory be patients. closer significant step milestone reduce a the the treatment The immunosuppressive patient overall to or this likelihood that creating exists, of transformative goal of such organ regulatory that relieve and a one risks minimize of burden method with the therapy
As a of potential that reminder, this is range CAR-Tregs working address develop of to conditions. therapies the autoimmune in first pipeline are to a
in active platform. development an to disease progress to our candidates inflammatory alongside allogeneic cell with and preclinical multiple In sclerosis Sangamo therapy multiple to TXXXX, addition the treat pipeline has efforts bowel
to or advised trial authority. turn investigational gene Chief research has it on expected this dosing resume now toward Jason XXXX Fontenot, updated of us trial, updates preclinical fitelparvovec, quarter including Pivotal I for Officer, Pfizer our in A, all the conditions of expect an III regarding hemophilia Finally, necessary by AFFINE Phase Jason? call the are protocols evaluating over an to of is readout giroctocogene end programs. Pfizer early approval XXXX. for to study, regulatory met, our will that with data continues Scientific the provided therapy guidance
